- Active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
For: Malignant Solid Tumor · Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC)United States · Denmark · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-Label Study of Pralsetinib versus Standard Of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
This study is looking at a new drug called Pralsetinib for advanced lung cancer where a specific genetic change (RET fusion) is present. It compares Pralsetinib to standard treatments to see if it works better or has fewer side effects for people who haven't had treatment for this type of cancer before.
For: RET fusion−positive · metastatic Non-Small Cell Lung CancerFrance · Netherlands · Belgium - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.
For: Metastatic Non-small Cell Lung CancerUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer. It combines standard chemotherapy with newer drugs, pembrolizumab and olaparib, to see if this mix works better than current treatments in slowing down cancer growth and helping people live longer and feel better.
For: Stage IV lung cancer conditionRomania · Austria · Germany - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
For: Advanced Non-small Cell Lung Cancer · HER2 MutationUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)
This study is looking at new treatments for advanced lung cancer. It combines standard chemotherapy with a drug called pembrolizumab, sometimes adding another drug called canakinumab, to see if this mix is more effective and safe for patients.
For: Non-small cell lung cancerSpain · Germany - Active not recruitingPHASE1
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
This study looks at a new drug, Amivantamab, alone or with other treatments, for certain types of advanced lung cancer. We want to find the safest and most effective dose, and see how well it works.
For: Non-Small-Cell Lung CancerUnited States · Australia · Canada - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This study aims to see if adding the drug pembrolizumab to standard chemotherapy before and after surgery helps people with early-stage non-small cell lung cancer live longer and prevent the cancer from returning. It's a large study comparing this new approach with chemotherapy alone.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study compares a new treatment called Sacituzumab Tirumotecan with standard care for recurrent or metastatic cervical cancer. It aims to see if the new treatment improves how long people live when current treatments aren't enough.
For: Cervical CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
This study looks at new drug combinations for a specific type of advanced lung cancer. It compares a new drug, Divarasib, with Pembrolizumab, against standard treatments to see which works best and is safest for patients with KRAS G12C-mutated non-small cell lung cancer.
For: Non-Small Cell Lung Cancer · KRAS G12C Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This early-stage study is testing a new drug, INBRX-109, for people with advanced solid tumours, including certain types of Ewing sarcoma and bowel cancer. Researchers want to see if it's safe and how well it works, both alone and with standard treatments. This is for patients who haven't responded to previous therapies.
For: Ewing Sarcoma · Colorectal AdenocarcinomaUnited States · France · Italy - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
For: Non-small Cell Lung Cancer (NSCLC)United States · Australia · Brazil - RecruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
For: Carcinoma, Non-Small-Cell Lung · Neoplasm MetastasisUnited States · Australia · Austria - Active not recruitingPHASE1
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
This study is testing a new medicine, IOA-244, for people with certain advanced cancers, including lymphoma and melanoma. It aims to see if the medicine is safe and if it can help the body's immune system fight cancer, both alone and with other treatments.
For: Solid Tumor, Adult · Non-Hodgkin Lymphoma, Adult · NSCLCItaly · United Kingdom - RecruitingPHASE2, PHASE3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
This study is testing a new drug called pumitamig, combined with usual chemotherapy and other drugs, for people with a type of lung cancer called non-small cell lung cancer. It aims to see if this new combination is safe and works well.
For: Non-small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study looks at a new drug, zongertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares zongertinib to standard treatment to see if it can better slow down cancer growth and improve how long people live without their cancer getting worse.
For: Lung Cancer, Non-squamous, Non-small CellUnited States · Argentina · Australia - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations to treat advanced lung cancer. It compares two different drug mixes, each including chemotherapy, to see which works best and is safest for people with Stage IV or recurrent non-small cell lung cancer.
For: Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Metastatic Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
This study compares a new treatment, Volrustomig combined with standard chemotherapy, against existing treatments for advanced mesothelioma. It aims to see if the new combination is safer and more effective for patients whose cancer can't be removed by surgery.
For: Unresectable Pleural MesotheliomaUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
For: Non-Small Cell Lung CancerUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
This study looks at new drug combinations for advanced lung cancer (non-small cell lung carcinoma) that has specific genetic changes (EGFR mutation) and has stopped responding to a previous treatment called osimertinib. It compares these new drug combinations with standard chemotherapy.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
This study looks at a new combination of treatments for a type of advanced lung cancer. It compares a drug called amivantamab plus standard chemotherapy to chemotherapy alone, to see if the combination works better at stopping the cancer from growing.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Belgium - Active not recruitingPHASE3
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
This study compares a new drug, TAK-788, with standard chemotherapy for advanced lung cancer (NSCLC) where the cancer has a specific genetic change (EGFR exon 20 insertion mutation). It's for people who haven't had prior treatment for their advanced cancer.
For: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)United States · Australia · Austria - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
This study looks at new drug combinations for advanced lung cancer. It combines telisotuzumab adizutecan with immune-boosting drugs like budigalimab or pembrolizumab. The goal is to find safe and effective doses to help people with non-small cell lung cancer who haven't had prior treatment for advanced disease.
For: Non Small Cell Lung CarcinomaUnited States · Belgium · China - Active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
For: Advanced Malignancies · NSCLC · Ovarian CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
For: Non-small Cell Lung CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This study looks at new ways to treat a type of lung cancer before surgery. We're testing a drug called osimertinib, either alone or with chemotherapy, against chemotherapy by itself. The goal is to see if these new treatments can help more people with resectable non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Austria · Brazil - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
For: Lung Neoplasms · Carcinoma, Non-Small-Cell LungUnited States · Argentina · Canada - Active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
For: NSCLCUnited States · Austria · Brazil - Active not recruitingPHASE3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
This study looks at a new combination of medicines, savolitinib and osimertinib, for people with a type of lung cancer that has gotten worse after treatment with osimertinib. It compares this new combination to standard chemotherapy to see if it works better and is safe.
For: Carcinoma · Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
For: Metastatic Non-small Cell Lung Cancer With MTAP DeletionUnited States · Argentina · Australia - Ongoing, recruitingPhase III and phase IV (Integrated)
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC (KEYVIBE-006)
This study is looking at new ways to treat advanced lung cancer that can't be removed by surgery. It compares a new combination of medicines with a standard treatment, both given with chemotherapy and radiotherapy, to see which works best.
For: Non-small cell lung cancerSpain · Italy · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
This study looks at a new combination of treatments for advanced non-small cell lung cancer. It compares a new drug (MK-7684A) plus chemotherapy to an existing drug (pembrolizumab) plus chemotherapy, to see which works better and is safer.
For: Metastatic Non-Small Cell Lung CancerGermany · Spain · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
This study is testing a new drug (Tisotumab Vedotin) for cervical cancer that has come back or spread, and hasn't responded to previous treatments. It compares whether the new drug works better than standard chemotherapy to help people live longer.
For: Second- or Third-Line Recurrent or Metastatic Cervical CancerSweden · Czechia · Finland - Ongoing, recruitingTherapeutic exploratory (Phase II)
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
This study is testing different new drug combinations with pembrolizumab and chemotherapy for people with advanced non-small cell lung cancer who haven't had treatment yet. It's looking at how well the new combinations shrink tumors and if they have side effects.
For: non-small cell lung cancerItaly · Hungary · Poland - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
This study looks at new drug combinations for advanced lung cancer. It combines bemcentinib with standard treatments like chemotherapy and immunotherapy. We want to see if these new combinations are safe and effective for people with this type of lung cancer, including those with a specific gene change (STK11 mutation).
For: Untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.France · Italy · Greece - Ongoing, recruitingTherapeutic exploratory (Phase II)
Open-label, Phase 2 study of tusamitamab ravtansine (SAR408701) combined with pembrolizumab and tusamitamab ravtansine (SAR408701) combined with pembrolizumab and platinum-based chemotherapy with or without pemetrexed in patients with CEACAM5-positive expression advanced/metastatic nonsquamous non-small-cell lung cancer (NSQ NSCLC)
This study is testing new combinations of medicines for a type of advanced lung cancer. It combines an experimental drug (tusamitamab ravtansine) with existing treatments like pembrolizumab (Keytruda) and chemotherapy to see how safe and effective they are. It's for adults whose cancer has a specific marker called CEACAM5.
For: CancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies
This study looks at a new combination of existing medicines for a type of lung cancer (NSCLC) that has worsened after previous treatments. It aims to see how many patients respond positively to this new treatment approach.
For: Lung Cancer · NSCLCFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) (PACIFIC2)
This study looks at a new drug called Imfinzi for people with a type of lung cancer that has spread nearby but can't be removed by surgery. It aims to see if Imfinzi, along with standard treatments like chemotherapy and radiation, helps people live longer and keeps the cancer from growing.
For: Patients with Locally Advanced · Unresectable Non-small Cell Lung Cancer (Stage III)Poland · Hungary - Active not recruitingPHASE3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This study compares a new treatment, Atezolizumab, to standard care for patients with early-stage lung cancer after surgery and chemotherapy. It aims to see if Atezolizumab can prevent the cancer from returning and help people live longer.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
This study looks at a new way to give a cancer drug called amivantamab, by injection under the skin instead of through a drip. It aims to see how well it works and if it's safe for people with advanced lung cancer, especially those with specific genetic changes.
For: Carcinoma, Non-small-Cell LungUnited States · Brazil · China - Active not recruitingPHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study looks at new drug combinations for advanced lung cancer. It compares a new drug (Datopotamab Deruxtecan) with an existing treatment (Pembrolizumab) and chemotherapy, to see if the new combinations are safer and work better.
For: Metastatic Non Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This study compares a new drug, alectinib, with standard chemotherapy for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after surgery. We want to see if alectinib is better at stopping the cancer from coming back and if it's safe.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Austria - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
This study is looking into a new drug, zipalertinib, for people with a certain type of lung cancer (NSCLC) in its early stages. It compares zipalertinib with standard chemotherapy to a dummy pill (placebo) with standard chemotherapy after surgery.
For: NSCLC, Stage IB-IIIA · Lung Cancer · AdjuvantUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
This study looks at a new drug, selpercatinib, for people with a type of lung cancer that has spread. It compares this new drug to standard treatments to see if it's safe and works well for their specific cancer type.
For: Non-Small Cell Lung CancerArgentina · Australia · Belgium - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia